Summary:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment
Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of
BIIB054 in Subjects with Parkinson’s Disease
Qualified Participants Must:
• Patients aged 40 to 80 years
Qualified Participants May Receive:
Compensation for time and travel